LONDON (Reuters Health) – Swiss healthcare group Roche said on Wednesday it has stopped marketing Valium (diazepam) in Britain because it is no longer commercially viable.
A spokeswoman for the UK arm of company stressed that this was a local decision and that other subsidiaries may continue selling the famous sedative.
Valium was introduced in 1963 and proved a huge commercial success even though critics said it could induce dependency.
Having lost patent protection many years ago, it is no longer commercially important for Roche. However generic companies will continue to market diazepam in Britain.